Cargando…

Cohort Study of Insulin Glargine and Risk of Breast, Prostate, and Colorectal Cancer Among Patients With Diabetes

OBJECTIVE: To examine whether use of insulin glargine, compared with another long-acting insulin, is associated with risk of breast, prostate, colorectal cancer, or all cancers combined. RESEARCH DESIGN AND METHODS: Computerized health records from Kaiser Permanente Northern and Southern California...

Descripción completa

Detalles Bibliográficos
Autores principales:	Habel, Laurel A., Danforth, Kim N., Quesenberry, Charles P., Capra, Angela, Van Den Eeden, Stephen K., Weiss, Noel S., Ferrara, Assiamira
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2013
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3836110/ https://www.ncbi.nlm.nih.gov/pubmed/24170756 http://dx.doi.org/10.2337/dc13-0140

Ejemplares similares

Cohort Study of Pioglitazone and Cancer Incidence in Patients With Diabetes
por: Ferrara, Assiamira, et al.
Publicado: (2011)

Response to: Analyses Using Time-Dependent Pioglitazone Usage in Cox Models May Lead to Wrong Conclusions About Its Association With Cancer
por: Habel, Laurel, et al.
Publicado: (2011)

Patients Diagnosed With Diabetes Are at Increased Risk for Asthma, Chronic Obstructive Pulmonary Disease, Pulmonary Fibrosis, and Pneumonia but Not Lung Cancer
por: Ehrlich, Samantha F., et al.
Publicado: (2010)

Impact of type 2 diabetes on lower urinary tract symptoms in men: a cohort study
por: Van Den Eeden, Stephen K, et al.
Publicado: (2013)

Central obesity increases the risk of gestational diabetes partially through increasing insulin resistance
por: Zhu, Yeyi, et al.
Publicado: (2018)

Liver Enzymes in Early to Mid-pregnancy, Insulin Resistance, and Gestational Diabetes Risk: A Longitudinal Analysis
por: Zhu, Yeyi, et al.
Publicado: (2018)

Insulin glargine overdose
por: Doğan, Fatma Sarı, et al.
Publicado: (2012)

California Men's Health Study (CMHS): a multiethnic cohort in a managed care setting
por: Enger, Shelley M, et al.
Publicado: (2006)

Duration of action of two insulin glargine products, LY2963016 insulin glargine and Lantus insulin glargine, in subjects with type 1 diabetes mellitus
por: Linnebjerg, Helle, et al.
Publicado: (2016)

Insulin glargine and the risk of cancer
por: Ahmed, FA
Publicado: (2010)

Associations between infant growth and pubertal onset timing in a multiethnic prospective cohort of girls
por: Aghaee, Sara, et al.
Publicado: (2022)

Immunogenicity and Efficacy of Insulin Glargine Biosimilar Ezelin versus Originator Insulin Glargine in Patients with Type 2 Diabetes
por: Tarigan, Tri Juli Edi, et al.
Publicado: (2021)

Maternal Microbial Metabolites and Risk of Fetal Growth Extremes: A Longitudinal Multi-Racial/Ethnic Cohort Study
por: Chehab, Rana, et al.
Publicado: (2022)

Prostatitis, Sexually Transmitted Diseases, and Prostate Cancer: The California Men's Health Study
por: Cheng, Iona, et al.
Publicado: (2010)

Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml
por: Steinstraesser, A, et al.
Publicado: (2014)

Lactation Intensity and Postpartum Maternal Glucose Tolerance and Insulin Resistance in Women With Recent GDM: The SWIFT cohort
por: Gunderson, Erica P., et al.
Publicado: (2012)

A case of hypersensitivity to soluble and isophane insulins but not to insulin glargine
por: Belhekar, Mahesh N., et al.
Publicado: (2015)

Efficacy and safety of LY2963016 insulin glargine in patients with type 1 and type 2 diabetes previously treated with insulin glargine
por: Hadjiyianni, I., et al.
Publicado: (2016)

Immunogenicity of LY2963016 insulin glargine and Lantus® insulin glargine in Chinese patients with type 1 or type 2 diabetes mellitus
por: Wang, Weimin, et al.
Publicado: (2022)

Dose-Response Effects of Insulin Glargine in Type 2 Diabetes
por: Wang, Zhihui, et al.
Publicado: (2010)

Evaluation of immunogenicity of LY2963016 insulin glargine compared with Lantus® insulin glargine in patients with type 1 or type 2 diabetes mellitus
por: Ilag, L. L., et al.
Publicado: (2016)

Glargine and degludec: Solution behaviour of higher dose synthetic insulins
por: Adams, Gary G., et al.
Publicado: (2017)

Pregravid Liver Enzyme Levels and Risk of Gestational Diabetes Mellitus During a Subsequent Pregnancy
por: Sridhar, Sneha B., et al.
Publicado: (2014)

Insulin Glargine: A Reevaluation of Rodent Carcinogenicity Findings
por: Stammberger, Ingo, et al.
Publicado: (2012)

A Salutary Tale—Glargine insulin and cancer risk
por: Boyle, Peter
Publicado: (2009)

Insulin Glargine and Acarbose in the treatment of elderly patients with diabetes
por: Li, Jing, et al.
Publicado: (2019)

Insulin-glargine/norepinephrine: Lack of efficacy: case report
Publicado: (2022)

Different slopes for different folks: socioeconomic and racial/ethnic disparities in asthma and hay fever among 173,859 U.S. men and women.
por: Chen, Jarvis T, et al.
Publicado: (2002)

Insulin glargine use and breast cancer risk: Associations with cumulative exposure
por: Peeters, Paul J. H. L., et al.
Publicado: (2016)

Protocol to Assess the Biological Activity of Insulin Glargine, Insulin Lispro, and Insulin Aspart In Vitro
por: Garige, Mamatha, et al.
Publicado: (2023)

Imputation of the Rare HOXB13 G84E Mutation and Cancer Risk in a Large Population-Based Cohort
por: Hoffmann, Thomas J., et al.
Publicado: (2015)

COVID-19 related changes in perinatal health care delivery and outcomes among pregnant individuals and newborns
por: Greenberg, Mara, et al.
Publicado: (2023)

Glargine insulin: an alternative to regular insulin for glycemic control in critically ill patients
por: Bhattacharyya, M, et al.
Publicado: (2007)

Insulin Detemir Versus Insulin Glargine in the Hospital: Do Hypoglycemia Rates Differ?
por: Crisher, Michelle A., et al.
Publicado: (2019)

Insulin glargine and risk of cancer: a cohort study in the French National Healthcare Insurance Database
por: Blin, P., et al.
Publicado: (2012)

Association of Glyburide and Subcutaneous Insulin With Perinatal Complications Among Women With Gestational Diabetes
por: Hedderson, Monique M., et al.
Publicado: (2022)

Insulin Glargine in the Treatment of Type 1 and Type 2 Diabetes
por: Barnett, Anthony H
Publicado: (2006)

Insulin Glargine Controversy: A Tribute to the Editorial Team at Diabetologia
por: Butler, Peter C.
Publicado: (2009)

In Vitro Metabolic and Mitogenic Signaling of Insulin Glargine and Its Metabolites
por: Sommerfeld, Mark R., et al.
Publicado: (2010)

Insulin Glargine Safety in Pregnancy: A transplacental transfer study
por: Pollex, Erika K., et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_mpeb77b7dv6p7s1i8ovbvfkd5u